Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

581 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease. The study will evaluate the clinical utility of a gene expression test Corus CAD (Age, Sex, Gene Expression Score - ASGES) in subjects referred for myocardial perfusion imaging (MPI) work-up for suspected obstructive atherosclerotic coronary artery disease (CAD). The Corus CAD (ASGES) is a gene expression test that quantify the expression of multiple genes from circulating peripheral blood cells to detect the presence of clinically significant obstructive CAD in patients with chest pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease

NCT01557855

Coronary Artery Disease Angina Pectoris Chest Pain +5 more

COMPLETED

PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis

NCT01594411

Chest Pain Cardiovascular Diseases Angina Pectoris +5 more

COMPLETED

Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.

NCT02405754

Coronary Artery Disease Angina Pectoris Chest Pain +5 more

COMPLETED

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

NCT00500617

Coronary Artery Disease Angina Pectoris Chest Pain +5 more

COMPLETED

Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making

NCT02223286

Coronary Artery Disease Angina Pectoris Chest Pain +5 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, multicenter study obtained peripheral blood samples for gene expression score (GES) before MPI in 537 consecutive patients Patients with abnormal MPI usually underwent invasive coronary angiography; all others had research coronary computed tomographic angiography, with core laboratories defining coronary anatomy A total of 431 patients completed GES, coronary imaging (invasive coronary angiography or computed tomographic angiography), and MPI Mean age was 56±10 years (48% women) The prespecified primary end point was GES receiver-operating characteristics analysis to discriminate ≥50% stenosis (15% prevalence by core laboratory analysis) Area under the receiver-operating characteristics curve for GES was 0 79 (95% confidence interval, 0 73-0 84; P\<0 001), with sensitivity, specificity, and negative predictive value of 89%, 52%, and 96%, respectively, at a prespecified threshold of ≤15 with 46% of patients below this score The GES outperformed clinical factors by receiver-operating characteristics and reclassification analysis and showed significant correlation with maximum percent stenosis. Six-month follow-up on 97% of patients showed that 27 of 28 patients with adverse cardiovascular events or revascularization had GES \>15 Site and core-laboratory MPI had areas under the curve of 0 59 and 0 63, respectively, significantly less than GES.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Chest Pain Cardiovascular Diseases Coronary Heart Disease Angina Pectoris CAD CVD CHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Corus CAD (ASGES)

Age/Sex/Gene Expression Score - ASGES

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 45-90 for women; 35-90 for men.
* Stable chest pain syndrome (typical or atypical) or anginal equivalent in the judgment of the investigator (e.g., pain in the neck, jaw, arm or shoulder or dyspnea possibly due to cardiac ischemia).
* Referred for a stress test using MPI.
* The patient has signed the appropriate Institutional Review Board approved Informed Consent Form.

Exclusion Criteria

* History of known MI or significant CAD.
* Current MI or acute coronary syndrome.
* Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms.
* Severe regurgitant or stenotic cardiac valvular lesion.
* Severe left ventricular systolic dysfunction (LVEF ≤ 35 % documented in the last year); if no assessment was performed or documented in the year preceding enrollment, presume normal LVEF.
* Active systemic infection (diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to fever, leukocytosis, positive blood cultures, pneumonia, urinary tract infection, or abscess in the preceding 2 months) or chronic infection (e.g., HIV, Hepatitis B or C, Tuberculosis).
* Protocol-specified rheumatologic, autoimmune or hematologic conditions (e.g., rheumatoid arthritis, systemic lupus erythematosis, polymyalgia rheumatica, or systemic sarcoidosis).
* Known or suspected diabetes mellitus or documented Hemoglobin A1c (HbA1c) ≥ 6.5; presume normal HbA1c if none documented.
* Total WBC ≥ 11,000 cells/ul and platelet count ≤ 75,000 cells/ul from a CBC with differential drawn within 7 days prior to enrollment \[WBC ≥ 11,000 cells/ul and platelet count ≤ 75,000 cells/ul from a CBC drawn \> 7 days prior need to be re-drawn at enrollment\].
* Recipient of any organ transplant.
* Immunosuppressive or immunomodulatory therapy including any dose of systemic corticosteroids in the preceding 2 months.
* Chemotherapy in the preceding year.
* Major surgery in the preceding 2 months.
* Blood or blood product transfusion in the preceding 2 months.
* Subjects for whom all forms (stress or pharmacologic) of MPI are contraindicated.
* Subjects for whom invasive coronary angiography or coronary CT angiography is contraindicated, including IV beta-blocker.
* Subjects who planned to decline research CCTA or invasive coronary angiography, regardless of MPI result.
* Subjects with history of atrial fibrillation/flutter or frequent irregular or rapid heart rhythms.
* Known history of renal insufficiency (serum creatinine ≥ 2.0 mg/dL), or severe allergy to iodinated contrast.

Minimum Eligible Age

35 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No